In this week’s news, Quanticate has partnered with Cancer Research UK, to launch the DETERMINE study, dMed | Clinipace has announced the name change to Caidya, and more.

Quanticate, a global data-focused clinical research organization (CRO), has partnered with leading cancer research organization, Cancer Research UK, to launch the DETERMINE study, which will test a range of therapies specifically targeting key genetic changes in cancer cells.

The first of its kind in the UK, the DETERMINE study will enroll patients with rare cancers, and aim to find out whether existing licensed drugs could be used to treat their type of cancer.

dMed | Clinipace has announced a corporate name change to Caidya. The name change reflects the successful integration of the legacy brands after their merger last year. Caidya offers the market a unique proposition with a clear focus on delivery excellence to help organizations activate the full potential of their science.

Genezen has delivered the next phase of its cGMP lentiviral and retroviral vector production facility expansion in Fishers, Indiana (US) to help meet increased lentiviral and retroviral GMP vector demand.

Though 2022 has been a down year for the biotechnology sector, notable decisions from the Food and Drug Administration have provided a few bright spots. The regulator could soon approve medicines from Apellis, Gilead and GSK, and decide whether to pull a controversial preterm birth drug from the market.  

Pfizer recently announced an agreement with Global Fund to supply up to 6 million treatment courses of its COVID-19 oral treatment, PAXLOVID as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary vessel for providing grant support to low-and-middle-income countries to purchase COVID-19 tests, treatments, and personal protective equipment.

Also in the news

Eisai and Biogen announced positive results from Eisai’s large global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, which met the primary endpoint and reduced clinical decline in early stages of Alzheimer’s disease. Lecanemab (BAN2401) is an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain.

CDMO trends

Some developments of note in the contracting sector:  

Samsung Biologics is drawing the industry’s attention by preemptively launching a CDMO business targeting the growing market of bispecific antibody medical products. The company said Thursday that it has released “S-DUAL,” an independently developed bispecific antibody platform.

The global Investigational New Drug CDMO market is estimated to reach over USD 7.47 billion by 2030, exhibiting a CAGR of 5.56% during the forecast period. 

Avid Bioservices, Inc. (NASDAQ:CDMO – Get Rating) Director Richard B. Hancock sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The shares were sold at an average price of $18.43, for a total value of $92,150.00. Following the completion of the sale, the director now owns 36,881 shares of the company’s stock, valued at $679,716.83.